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Abstract 
Review on PF4, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: CXCL4, PF-4, SCYB4 
HGNC (Hugo): PF4 
Location: 4q13.3 
Note 
The platelet factor CXCL4 is a rather atypical 
chemokine because its leukocyte chemoattractant 
activity is not that prominent. However, CXCL4 
influences a large range of processes via interaction 
with a diversity of cellular receptors. These 
receptors are expressed on leukocytes, endothelial,  
epithelial and mesangial cells and also tumor cells 
and involve classical chemokine receptors as well 
as glycosaminoglycans (GAG). Its most prominent 
activity is inhibition of angiogenesis and, 
consequently, of tumor growth and metastasis. 
The general biology of CXCL4 has been reviewed 
elaborately by different groups (Aidoudi and 
Bikfalvi, 2010; Kasper and Petersen, 2011; 
Vandercappellen et al., 2011). 
DNA/RNA 
Note 
The CXCL4 gene is located in the CXC chemokine 
gene cluster on chromosome 4q, in close proximity 
of its variant gene PF-4var/PF-4alt/CXCL4L1. The 
gene and mRNA for CXCL4 are 1300 and 855 bp 
in length, respectively. 
 
Figure 1. Structure of the human CXCL4 gene. This figure schematically depicts the structure of the human CXCL4 gene as 
described in the NCBI database (NM_002619). Lines represent the introns, whereas rectangular exons are coloured blue, yellow 
and green to represent the non-coding domains, the signal peptide and the mature protein, respectively. Grey numbers indicate 
the basepair numbering in the CXCL4 mRNA. Red numbers apply to the amino acids encoded. 
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Description 
The CXCL4 mRNA is encoded by three exons as 
depicted in figure 1.  
Alternative splicing of the gene has not been 
reported. 
Transcription 
The CXCL4 mRNA is predominantly present in 
platelets, but has also been detected in monocytes, 
T cells, T cell clones, human aortic smooth muscle 
cells, the colorectal adenocarcinoma cell line HCT-
8. 
Pseudogene 
None. 
Protein 
Note 
CXCL4 precursor: 101 amino acids (aa), 10844.9 
Da; CXCL4 mature: 70 aa, 7765.2 Da; 
Alternatively spliced signal peptide CXCL4: 74 aa, 
8141.5 Da. Several NH2-terminally truncated 
forms. 
Description 
CXCL4 is a member of the CXC chemokine family 
of chemoattractant cytokines. CXCL4 is a non-ELR 
CXC chemokine, meaning that it lacks the sequence 
glutamic acid-leucine-arginine just in front of the 
two NH2-terminally located conserved cysteine 
residues. 
Expression 
CXCL4 is stored in secretory granules and released 
in response to protein kinase C activation. For 
example, in platelets the CXCL4 protein is stored in 
the alpha-granules and released upon activation by 
e.g. thrombin as a homotetramer bound to 
chrondroitin-4-sulphate on a carrier protein. 
Therefore, CXCL4 is present at high concentrations 
in thrombi and concentrations in serum reach levels 
of 10 µg/ml. CXCL4 protein has also been detected 
in mast cells by immunohistochemistry, and is 
released by monocytes (100 ng/ml), activated T 
cells, cultured microglia (1 ng/ml) and the 
colorectal adenocarcinoma cell line HCT-8 (0.5 
ng/ml). Finally, prostate cancer cell lines DU-145 
and PC-3 were shown to express CXCL4. 
Localisation 
Secreted or stored in intracellular granules. 
Function 
The first extracellular molecules binding CXCL4 
were identified to be chrondroitin-sulphate-
containing proteoglycans (Figure 2). These GAG  
 
 
mediate the effects of CXCL4 on  
monocytes and neutrophils and pass intracellular 
signals to tyrosine kinases of the Src family, 
members of the MAP kinase family and monomeric 
GTPases. CXCL4 also has high affinity for heparin 
and heparan sulphate.  
Through its ability to bind and neutralize heparin, 
CXCL4 influences blood coagulation. More so, the 
interaction of CXCL4 with heparan sulphate 
proteoglycans on endothelial cells is responsible for 
the rapid clearance of CXCL4 from the circulation 
and prevents degradation of the chemokine. 
Besides binding to GAG, CXCL4 has also been 
described to bind several growth factors, such as 
VEGF and FGF-2, and other chemokines, including 
CCL2/MCP-1 and possibly CXCL12/SDF-1 
(Carlson et al., 2012).  
This heteromultimerisation, sequestering 
angiogenic proteins, explains at least in part the 
anti-angiogenic effect of CXCL4.  
Heteromer formation of CXCL4 with 
CCL5/RANTES also affects monocyte recruitment 
(Koenen et al., 2009), and possibly atherogenesis. 
Although proteoglycans are mostly considered to be 
"co- receptors", the high affinity of CXCL4 for 
GAG was for a long time thought to mediate most, 
if not all, of its biological functions since no GPCR 
for CXCL4 was identified.  
However, Lasagni et al. identified a splice variant 
of CXCR3, which was named CXCR3B, as a 
functional GPCR for CXCL4.  
Currently, CXCL4 is known to activate both 
CXCR3A and CXCR3B (Figure 2).  
In general, proliferative and positive migratory 
effects are supposed to be mediated by CXCR3A, 
whereas inhibition of chemotaxis, anti-proliferative 
and apoptotic effects are postulated to be provoked 
via CXCR3B. 
Homology 
CXCL4 is most closely related to its variant 
CXCL4L1, a non-allelic variant found only in 
primates. In men, mature proteins only differ in 3 
amino acids. 
Mutations 
Note 
CXCL4 appears to behave as a tumor suppressor 
gene. In multiple myeloma, CXCL4 is frequently 
silenced as a consequence of promoter 
hypermethylation (Cheng et al., 2007). 
Furthermore, a subclass of acute lymphoblastic 
leukemia patients exhibits a common translocation 
with a breakpoint distal to the CXCL4 gene (Arthur 
et al., 1982; Griffin et al., 1987). 
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Figure 2. Signaling pathways activated by CXCL4. A complex signaling network lies at the basis of the functional diversity of 
CXCL4. This network integrates several cascades initiated by different cellular receptors, including the G-protein-coupled 
receptors (GPCR) CXCR3A (Gi) and CXCR3B (Gs). CXCL4 also displays an exceptional high affinity for the glycosaminoglycans 
chains on membrane-embedded proteoglycans, hypothesized to initiate signaling cascades of their own (Kasper and Petersen, 
2011). The schematic network depicted here represents a selection of prominent CXCL4-activated pathways and provides 
insight into the complexity of CXCL4 signaling, yet does not provide an exhaustive list of all signaling molecules implicated. 
Target cells for CXCL4 include leukocytes (neutrophils, monocytes, activated T cells, dendritic cells, NK cells and mast cells), 
endothelial cells, airway epithelial cells, hepatic stellate cells, mesangial cells and vascular pericytes. 
 
 
Implicated in 
Leukemia and myeloma 
Prognosis 
Serum proteome profiling revealed decreased serum 
levels of CXCL4 as a biomarker for advanced 
myelodysplastic syndrome (MDS), often 
progressing to acute myeloid leukemia (AML) 
(Aivado et al., 2007). Other studies have 
corroborated involvement of CXCL4 over the 
course of MDS and AML and have recognized the 
chemokine as a prognostic, therapy-associated 
marker indicative of response to therapy, blood 
count recovery and eventual clinical outcome (Bai 
et al., 2013; Chen et al., 2010; Kim et al., 2008). 
Oncogenesis 
Evidence in acute lymphoblastic leukemia (ALL), 
showing a common translocation amongst a 
subclass of patients, with a breakpoint in 4q21 
which was later shown to be distal to the CXCL4 
gene, suggested the involvement of CXCL4 in ALL 
tumorigenesis (Arthur et al., 1982; Griffin et al., 
1987). More recently, decreased serum levels of 
CXCL4 have also been suggested to serve as a 
marker for pediatric ALL (Shi et al., 2009). In 
multiple myeloma CXCL4 was effectively 
identified as a tumor suppressor gene, frequently 
silenced as a consequence of promoter 
hypermethylation (Cheng et al., 2007). 
Osteosarcoma 
Disease 
The platelet-associated CXCL4 expression was 
found to be elevated shortly after implantation of 
human osteosarcoma in mice (Cervi et al., 2008). It 
has been proposed as a biomarker of early tumor 
growth. Alternatively, another recent study 
described plasma levels of CXCL4 to be elevated in 
pediatric osteosarcoma patients (Li et al., 2011). 
Prognosis 
Not only were plasma levels of CXCL4 in pediatric 
osteosarcoma patients shown to be significantly 
higher than those in controls, survival analysis 
further revealed that higher circulating levels of 
CXCL4 were associated with a poorer outcome (Li 
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et al., 2011). CXCL4 may prove to be a promising 
prognostic factor in osteosarcoma patients in the 
future. 
Liposarcoma 
Disease 
The platelet-associated CXCL4 expression, unlike 
its soluble plasma counterpart, was found to be 
elevated shortly after implantation of human 
liposarcoma in mice (Cervi et al., 2008). It has been 
proposed as a biomarker of early tumor growth. 
Mammary adenocarcinoma 
Disease 
The platelet-associated CXCL4 expression, unlike 
its soluble plasma counterpart, was found to be 
elevated shortly after implantation of human 
mammary adenocarcinoma in mice (Cervi et al., 
2008). It has been proposed as a biomarker of early 
tumor growth. 
Pancreatic adenocarcinoma 
Prognosis 
Discovery of a cancer-associated reduction of 
CXCL4 serum concentrations lead to the 
identification of CXCL4 as a discriminating marker 
in pancreatic cancer (Fiedler et al., 2009).  
Potential of CXCL4 as a diagnostic marker was 
shortly after confirmed (Poruk et al., 2010). 
Moreover, serum CXCL4 was also identified as a 
strong independent predictor of survival in this 
study, where decreased survival is associated with 
elevated CXCL4 levels.  
Finally, as a prognostic marker, CXCL4 may prove 
to be valuable in identifying patients at risk of 
complications and thus may benefit from 
prophylactic antithrombotic therapy (Poruk et al., 
2010). 
Colorectal cancer 
Disease 
Platelet content of CXCL4 in 35 patients with colon 
cancer was shown to be significantly increased 
when compared to 84 age-matched healthy controls 
(Peterson et al., 2012).  
Though not thought to be clinically relevant, a 
change in CXCL4 platelet levels was identified as a 
predictor of colorectal carcinoma which could 
potentially enable early diagnosis of disease. 
Prostate cancer 
Prognosis 
Recent in vitro research has evidenced that 
particular prostate tumor cells, namely DU-145 and 
PC-3 cells, exhibit a shift in CXCR3 splice variant 
presentation (Wu et al., 2012).  
In combination with the reported elevated tumor 
CXCL4 expression in vitro, these data suggest 
CXCL4 might promote in vitro migration and  
invasiveness of prostate cancer cells marked by a 
change in their CXCR3 expression pattern. 
However, CXCL4 levels have been described 
previously to be significantly decreased in the sera 
of all metastatic prostate carcinoma patients 
compared to healthy individuals, as well as 
compared to localized prostate carcinoma patients 
(Lam et al., 2005). 
Endometriosis-associated ovarian 
cancer (EAOC) 
Oncogenesis 
Both clear cell and endometrioid types of ovarian 
cancers occasionally develop on the bases of 
endometriosis.  
These endometriosis-associated ovarian cancers 
(EAOC) are characterized by infiltration of 
CXCL4-depleted tumor-associated macrophages, 
whereas in contrast, in pre-existing endometriosis 
CXCL4 is strongly expressed by CD68+ infiltrating 
macrophages (Furuya et al., 2012).  
Macrophage CXCL4 expression is thus associated 
with EAOC disease state and pre-malignant lesions. 
Metastatic carcinoma 
Disease 
Analysis of platelet content in a heterogeneous 
group of patients with newly diagnosed metastatic 
disease (including colorectal cancer, renal cell 
cancer, malignant fibrous histiocytoma, 
leiomyosarcoma and peripheral neuroectodermal 
cancer) a significant reduction in CXCL4 platelet 
concentrations was observed (Wiesner et al., 2010). 
Simultaneously, however, CXCL4 was upregulated 
in cancer patient plasma. 
Chemotherapy-induced 
thrombocytopenia (CIT) 
Prognosis 
CXCL4 may be a useful biomarker predicting the 
risk of thrombocytopenia developing with 
chemotherapy (CIT) (Lambert et al., 2012).  
Patients with low steady-state platelet CXCL4 
levels would better tolerate chemotherapy, whereas 
high concentrations may be an indication for CIT 
and predict the need for a platelet transfusion. 
Hepatitis and liver fibrosis 
Disease 
CXCL4 expression is enhanced in the liver of 
patients with advanced hepatitis C virus-induced 
fibrosis or nonalcoholic steatohepatitis and Cxcl4 
knock-out mice had significantly reduced 
histological and biochemical liver damage in an in 
vivo model for fibrotic liver disease (Zaldivar et al., 
2010).  
In vitro, recombinant mouse CXCL4 stimulated 
proliferation and chemotaxis of hepatic stellate 
cells. 
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Malaria 
Disease 
Acute Plasmodium falciparum infection, causing 
malaria characterized by especially high morbidity 
and mortality, leads to elevated plasma levels of 
platelet-specific proteins, including CXCL4 (Essien 
and Ebhota, 1983). On the one hand CXCL4 exerts 
a protective, antimalarial effect. Upon binding of 
platelets to infected red blood cells, locally released 
CXCL4 in particular instigates killing of 
intraerythrocytic P. falciparum parasites (Love et 
al., 2012; McMorran et al., 2013). The protective 
function of blood platelets and CXCL4 is 
dependent on the Duffy-antigen receptor 
(Fy/DARC) on the erythrocytes. On the other hand, 
CXCL4 mediates the pathogenesis of cerebral 
malaria (CM), a serious complication of P. 
falciparum infection (Wilson et al., 2011). CXCL4 
is believed to promote a pro-inflammatory 
environment and to contribute to disruption of the 
blood-brain barrier. 
Prognosis 
Wilson et al. have suggested a prominent role for 
CXCL4 in the pathogenesis of fatal CM and 
identified this chemokine as a potential prognostic 
biomarker for CM mortality (Wilson et al., 2011). 
Acquired immunodeficiency 
syndrome (AIDS) 
Disease 
Auerback et al. have identified CXCL4 as a unique 
broad-spectrum inhibitor of HIV-1 (Auerbach et al., 
2012).  
Through binding of the external viral envelope 
glycoprotein, gp120, CXCL4 interferes with the 
earliest events in the viral infectious cycle, namely 
attachment and entry, and consequently reduces 
replication of different phenotypic variants of HIV-
1 in CD4+ T cells and macrophages. In parallel, 
another study found activated platelets to release 
antiviral factors which suppress HIV-1 infection of 
T cells and confirmed CXCL4 to be a key player in 
this first line of defense against HIV-1 (Tsegaye et 
al., 2013). 
Prognosis 
Preliminary results reported by Auerback and 
colleagues suggest a correlation between higher 
serum levels of CXCL4 in HIV-1-infected patients 
and a less advanced clinical stage (Auerbach et al., 
2012). 
Heparin-induced thrombocytopenia 
(HIT) 
Disease 
Heparin is widely used as anti-coagulant during 
invasive vascular surgery and to treat thrombo-
embolic pathology. HIT is a rare (1-5%), paradoxal 
complication of anticoagulant heparin therapy in 
which patients having developed antibodies against 
CXCL4/heparin complexes, are at risk for venous 
as well as arterial thrombosis, despite low platelet 
counts (Rauova et al., 2010).  
Heparin is thought to act as an adjuvant integral to 
immunogenesis, whereas the HIT antibody 
recognizes antigenic epitopes within CXCL4 and 
thus the presence of CXCL4 is essential to the 
clinical manifestations caused by circulating 
antibodies (Prechel and Walenga, 2013). 
Rheumatoid arthritis 
Prognosis 
Increased levels of CXCL4 have been reported in 
the synovial fluid of patients with rheumatoid 
arthritis (Erdem et al., 2007).  
However, especially elevated plasma levels of 
CXCL4 in particular subsets of patients may be 
associated with clinical manifestation of 
rheumatoid arthritis, such as the occurrence of 
cutaneous vasculitis, and also correlate to a non-
response to anti-TNFα therapy (Trocme et al., 
2009; Yamamoto et al., 2002). 
Proliferative diabetic retinopathy 
(PDR) 
Disease 
Early on an association was recognized between 
diabetes and PDR on the one hand and elevated 
plasma levels of coagulation factors, such as 
CXCL4, on the other hand (Ek et al., 1982; Roy et 
al., 1988).  
Recent clinical studies have not only confirmed 
elevated CXCL4 levels in the vitreous fluid of PDR 
patients but also a correlation between vitreous 
CXCL4 concentration and PDR clinical disease 
activity (Nawaz et al., 2013).  
Vitreous levels of CXCL4 are significantly higher 
both in PDR with active neovascularisation and in 
PDR without traction retinal detachment. 
Inflammatory bowel disease (IBD) 
Disease 
Already in 1987, plasma CXCL4 concentrations 
were shown to be increased in patients with IBD 
disease (Simi et al., 1987).  
CXCL4 was later on identified as a biomarker for 
IBD using proteomic serum profiling (Meuwis et 
al., 2007).  
Though originally controversial, plasma CXCL4 
levels were confirmed to be positively correlated to 
disease activity in Crohn's disease (Vrij et al., 
2000). 
Prognosis 
Similar to their predictive role in rheumatoid 
arthritis, high CXCL4 plasma levels are indicative 
of non-responsiveness to anti-TNFα antibody 
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(infliximab) treatment in Crohn's disease (Meuwis 
et al., 2008). 
Atherosclerosis 
Disease 
The proatherogenic role of CXCL4 has been 
established in a variety of mostly preclinical studies 
(e.g. Sachais et al., 2007).  
CXCL4, released by activated platelets at injury 
sites, presumably promotes the progression of 
atherosclerotic lesions through different 
mechanisms.  
These include recruiting and arresting peripheral 
monocytes at the lesion site and consequently 
facilitating their differentiation into macrophages 
and concordant polarization as well as inhibiting 
degradation of LDL-R while increasing uptake and 
esterification of ox-LDL in macrophages (Aidoudi 
and Bikfalvi, 2010; Gleissner, 2012).  
The histological distribution of CXCL4 was also 
shown to be associated with the location and grade 
of vascular lesions (Pitsilos et al., 2003). Staining 
of macrophages for CXCL4 correlated with 
symptomatic atherosclerotic disease.  
Moreover, proinflammatory heteromer formation of 
CXCL4 with another platelet chemokine 
CCL5/RANTES has emerged as an additional 
regulatory mechanism, enhancing monocyte 
recruitment and thereby contributing to the disease 
progression (Koenen et al., 2009).  
Recently, a linkage study described an association 
between CXCL4 and platelet activation in human 
patients, thus linking this chemokine to the clinical 
manifestation of atherosclerosis (Bhatnagar et al., 
2012). 
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